Market Overview - US economic data reinforces expectations for interest rate cuts next week, with major US stock indices rising; S&P 500 approaches record highs, and Nasdaq sees four consecutive gains [1] - Nvidia experiences a slight decline of 0.5% but gains over 3% for the week; Tesla rises nearly 6% for the week [1] - PCE data leads to a rise in US Treasury yields, with the 10-year Treasury reaching its worst weekly performance in nearly eight months [1] Cryptocurrency - Cryptocurrency market sees a decline, with Bitcoin dropping nearly 5% and falling below $89,000 [2] Commodities - Silver and copper reach historical highs, with silver prices increasing over 4% [3] - Crude oil prices rise for three consecutive days, reaching a two-week high, with US oil closing above $60 for the first time in two weeks [4] Technology Developments - Nvidia announces CUDA 13.1, claiming it to be the largest update in 20 years for the CUDA platform [5] - SpaceX's valuation may double to $80 billion, surpassing OpenAI to become the highest-valued private company globally, with plans for an IPO in the second half of next year [6] - Microsoft is in talks with Broadcom for custom chip collaboration to reduce reliance on Nvidia [7] Corporate News - Apple faces significant executive turnover, with a potential departure of chip chief Johny Srouji, raising concerns about CEO Tim Cook's direction [8] - OpenAI is expected to release GPT-5.2 as early as Tuesday [9] Domestic Developments - China’s first regulatory framework for listed companies has been released, aiming to strengthen oversight of key executives and address financial fraud [11] - The Financial Regulatory Bureau adjusts risk factors for insurance companies investing in stocks to foster patient capital [11] - China’s foreign exchange reserves remain above $3.3 trillion for four consecutive months, with the central bank increasing gold holdings for 13 months [13] A-Share Market Strategy - Analysts expect a preemptive "spring rally" in the A-share market, driven by anticipated interest rate cuts from the Federal Reserve and upcoming policy meetings [17] - The market is expected to see increased foreign investment due to favorable currency conditions and regulatory adjustments [17] New Stock Offerings - Two new stocks are available for subscription: Nabai Chuan at 22.63 yuan per share and Youshun Co. at 51.66 yuan per share, both with significant market positions in their respective sectors [22] Company Announcements - Jiahua Technology plans to acquire 90% of Shudun Technology, focusing on domestic encryption technology [23] - Anni Co. announces a change in controlling shareholder, while Guoao Technology is planning a change in control [25]

Group 1 - The core announcement is that Yantai Dongcheng Pharmaceutical Group Co., Ltd.'s subsidiary, Yantai Lanacheng Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of the drug 177Lu-LNC1009 injection, which targets advanced malignant solid tumors [1][2] - The drug 177Lu-LNC1009 is a dual-target radioactive therapy aimed at FAP-positive and integrin αvβ3-positive patients, showing potential for improved tumor targeting and treatment efficacy [2][3] - The total research and development investment for 177Lu-LNC1009 has reached approximately 13.579 million yuan [2] Group 2 - The company announced that its full subsidiary, Nanjing Jiangyuan Andico Positron Research and Development Co., Ltd., has had its product, Technetium-99m (99mTc) Tetrofosmin injection, included in the National Medical Insurance Directory for 2025, which is expected to enhance market accessibility and promote sales [4] - The inclusion in the medical insurance directory will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's financial performance in the short term [4]

摘要 / 创造新的增量 嘿嘿，周五没什么好的段子，就没发文，唯一一个我觉得好笑的就是，保险券商 异动股的时候，群里传出小作文，说"会议重提jzjx"! 盘后保险业务相关因子调整的文件出来了，谁又知道内幕抢跑了！ 《通知》明确： 1）险资持仓时间超过三年的沪深300指数成分股、中证红利低波动100指数 成分股的风险因子从0.3下调至0.27，持仓时间根据过去6年加权平均持仓时 间确定。 2）险资持仓时间超过两年的科创板上市普通股的风险因子从0.4下调至 0.36，持仓时间根据过去4年加权平均持仓时间确定。 3）保险公司出口信用保险业务和中国出口信用保险公司海外投资保险业务的 保费风险因子从0.467下调至0.42，准备金风险因子从0.605下调至0.545。 根据申万宏源，以9月末水平静态测算，本次调降险资股票投资风险因子合计给A 股上市险企带来200亿元最低资本优化，调整后核心/综合偿付能力充足率平均提 升1.5/2.1pct。假设调整风险因子后，A股上市险企维持偿付能力充足度不变， 沪深300成分股(持有3年以上)的潜在增配空间达789亿元。 没有增量，创造增量也要上！ 这个拼音缩写大概率是降准降息，哈哈哈 ...

Group 1: Stock Resumption and Suspension - Jiahua Technology plans to acquire 90% of Shudun Technology, focusing on domestic cryptography technology research and information security solutions, leading to stock resumption [1] - Annie Co. will have Shengshi Tianan as its controlling shareholder, resulting in stock resumption [1] - ST Tianrui has terminated plans for a change in company control, leading to stock resumption [1] - Gu'ao Technology's actual controller is planning a change in control, resulting in stock suspension [1] Group 2: Share Buybacks and Increases - Meilixin's controlling shareholder intends to increase company shares by 50 million to 100 million yuan [2] Group 3: Investment Cooperation and Operational Status - Shangwa New Materials plans to purchase software code usage rights for 26 million yuan [3] - Hengdian East Magnet's chip inductors have entered major enterprises, achieving rapid shipment growth [3] - Roman Co.'s subsidiary signed a contract worth approximately 448 million yuan for computing power equipment sales and services [3] - Guangqi Technology's subsidiary signed a contract worth 696 million yuan to deliver metamaterial aerospace structural products [3] - Yanshan Technology's subsidiary Nullmax (Cayman) plans to introduce a leading domestic automotive-grade chip company as a strategic investor [3] - Aerospace Electric's subsidiary Suzhou Huazhan Investment is investing 57.25 million yuan to build production capacity for high-speed modules and liquid cooling interconnect products [3] - East China Pharmaceutical's wholly-owned subsidiary's products have been included in the national medical insurance and commercial insurance innovative drug catalog [3] - Fosun Pharma has multiple drugs newly included in the national medical insurance and commercial insurance innovative drug catalog [3] - Ailis's innovative drugs have been included in the new version of the national medical insurance catalog [3] - Aidi Pharmaceutical's two anti-HIV innovative drugs have renewed their entry into the national medical insurance catalog [3] - Dongcheng Pharmaceutical's 177Lu-LNC1009 injection clinical trial has been approved, with no similar products currently on the market [4] - Weike Technology primarily provides products such as robot motor insulation ends and has achieved mass sales, collaborating with global companies like DANFOSS [4] - Double Star New Materials has reached a consensus on production reduction in the BOPET industry under the "Industry Self-Discipline Initiative" [4] - Wanliyang has invested in production lines for precision transmission products for robot joints, expected to reach mass production by May 2026 [4]

智通财经APP讯，东诚药业(002675.SZ)发布公告，2025年12月5日，公司控股子公司烟台蓝纳成生物技 术股份有限公司(以下简称"蓝纳成")收到中国国家药品监督管理局(以下简称"国家药监局")核准签发的 关于Lu-LNC1009注射液的药品临床试验批准通知书，将于近期开展临床试验。 公司在研产品Lu-LNC1009注射液是一种靶向结合成纤维细胞激活蛋白(FAP)与整合素αvβ3的双靶点放射 性体内治疗药物，拟用于FAP阳性和整合素αvβ3阳性的晚期恶性实体瘤患者的治疗。目前国内外暂无同 产品上市，亦无相关销售数据。 ...

公司在研产品177Lu-LNC1009注射液是一种靶向结合成纤维细胞激活蛋白(FAP)与整合素αvβ3的双靶点 放射性体内治疗药物，拟用于FAP阳性和整合素αvβ3阳性的晚期恶性实体瘤患者的治疗。目前国内外暂 无同产品上市，亦无相关销售数据。 东诚药业（002675）(002675.SZ)发布公告，2025年12月5日，公司控股子公司烟台蓝纳成生物技术股份 有限公司(以下简称"蓝纳成")收到中国国家药品监督管理局(以下简称"国家药监局")核准签发的关于 177Lu-LNC1009注射液的药品临床试验批准通知书，将于近期开展临床试验。 ...

格隆汇12月7日丨东诚药业(002675.SZ)公告，2025年12月5日，烟台东诚药业集团股份有限公司(以下简 称"公司")控股子公司烟台蓝纳成生物技术股份有限公司(以下简称"蓝纳成")收到中国国家药品监督管理 局(以下简称"国家药监局")核准签发的关于177Lu-LNC1009注射液的药品临床试验批准通知书，将于近 期开展临床试验。 ...

东诚药业公告称，其全资子公司安迪科的锝替曲膦注射液被纳入《国家基本医疗保险、生育保险和工伤 保险药品目录（2025年）》。该产品仅用于诊断，可用于药物负荷和静息状态下心肌灌注显像。产品属 乙类注射剂，分类为心血管系统的诊断用放射性药物。《医保目录（2025年）》于2026年1月1日起执 行，暂不会对公司经营业绩构成重大影响。 ...

东诚药业公告称，其控股子公司蓝纳成收到国家药监局核准签发的177Lu - LNC1009注射液药品临床试 验批准通知书，近期将开展临床试验。该注射液是双靶点放射性体内治疗药物，拟用于治疗FAP阳性和 整合素αvβ阳性的晚期恶性实体瘤患者。目前国内外暂无同产品上市，相关项目累计已投入研发费用约 1357.90万元。药品研发至上市周期长、环节多，存在不确定性。 ...

锝[ 99mTc]替曲膦注射液被纳入《医保目录（2025年）》，提高患者对SPECT-MPI 检查的可及性，促进冠状动脉疾病诊疗精准化，将有利于该产品的市场推广及未 来销售。因《医保目录（2025 年）》将于 2026 年 1 月 1 日起正式执行，暂不会 证券代码：002675 证券简称：东诚药业 公告编号：2025-071 烟台东诚药业集团股份有限公司 关于锝[99mTc]替曲膦注射液纳入医保目录的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 二、对公司的影响及风险提示 药品名称 适应症 药品分 类代码 药品分类 编号 剂型 医保分类 锝[ 99mTc] 替曲膦注 射液 锝[ 99mTc]替曲膦注射液仅用 于诊断。在患有或疑似冠状 动脉疾病的成人中两次注射 液给药条件下，可用于药物 负荷和静息状态下心肌灌注 显像，以反映心肌血流灌注 变化。 XV09G 心血管系 统的诊断 用放射性 药物 399 注射剂 乙类 一、本次纳入《医保目录（2025 年）》产品信息 根据国家医疗保障局、人力资源社会保障部于 2025 年 12 月 7 日发布的《国 家基本 ...